TABLE 3.
Activities of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against antibiotic-resistant clinical and mouse isolates
| Organism(s) | Antibiotic resistance patterna | MICb (μg/ml) of:
|
|||
|---|---|---|---|---|---|
| Mutacin B-Ny266 | Nisin A | Vancomycin | Oxacillin | ||
| Neisseria meningitidis ATCC 13077 | LIN-TMP-VAN | 1.6 (1.6–3.2) | 6.3 (4.2–8.4) | >120 | 2.1 (2.1–4.2) |
| Neisseria gonorrhoeae | |||||
| 013x | AMP-LIN-OXA-PEN-TMP | 1.6 (0.8–3.2) | 4.2 (4.2–8.4) | 30.1 (30.1–42.6) | 127 (127–127) |
| 016 | AMP-LIN-OXA-PEN | 3.2 (1.6–3.2) | 8.4 (8.4–8.4) | 30.2 (15.1–30.2) | >127 |
| 017 | AMP-LIN-NEO-OXA-PEN-POB-TMP | 2.3 (1.6–3.2) | 8.4 (4.2–8.4) | 30.6 (30.1–42.6) | >127 |
| 022 | LIN-NEO-OXA-PEN-POB-SFX-TMP-VAN | 3.2 (2.2–6.4) | 12 (8.4–17) | 60 (30–120) | 32.7 (22.4–63.4) |
| 071940 | LIN-OXA-POB | 1.6 (1.6–1.6) | 4.2 (4.2–4.2) | 30.1 (30.1–60.2) | 9.8 (8.5–11.2) |
| 141 | LIN-NEO | 0.8 (0.8–1.6) | 5.9 (4.2–8.4) | 15.1 (8.0–30.1) | 0.6 (0.2–0.8) |
| 167 | AMP-LIN-OXA-PEN-TMP | 1.6 (0.8–1.6) | 7.1 (5.9–8.4) | 25.7 (15.1–60.2) | 95.1 (63.4–127) |
| 265 | POB-TMP | 1.6 (1.1–2.3) | 5.9 (5.9–8.4) | 21.3 (15.1–30.1) | 13.5 (11.2–15.9) |
| 31540 | OXA-POB-TMP | 3.1 (1.6–3.2) | 8.4 (5.9–11.8) | 72.7 (30.1–85.1) | 54.1 (31.7–63.4) |
| INF2 | LIN-OXA-POB-TMP-VAN | 2.3 (2.3–2.3) | 8.4 (8.4–8.4) | 60.2 (30.1–60.2) | 31.7 (15.9–31.7) |
| INF4 | LIN-NEO-OXA-POB-STR-TMP-VAN | 1.9 (1.1–3.2) | 7.1 (4.2–16.7) | 30.1 (30.1–30.1) | 15.9 (7.9–15.9) |
| Enterococcus faecalis | |||||
| ATCC 27275 | LIN-NAL-NEO-OXA-POB-STR-SFX-TET | 12.8 (12.8–25.6) | 14.3 (8.4–16.7) | 4.0 (2.0–4.0) | 8.4 (7.9–8.4) |
| 2D4.22 | LIN-NAL-NEO-OXA-POB-RIF-SFX | 15.5 (12.3–25.6) | 18.8 (16.7–33.4) | 2.0 (2.0–2.0) | 15.9 (15.8–31.7) |
| 2L5.07 | CEF-LIN-NAL-NEO-OXA-PEN-POB-STR-SFX | 6.4 (6.4–12.8) | 8.4 (8.4–16.7) | 1.9 (1.9–2.0) | 31.7 (15.8–63.4) |
| 78.4 and S1.17 | LIN-NAL-NEO-OXA-POB-STR-SFX | 3.2 (1.6–25.6) | 8.4 (8.4–23.6) | 2.0 (2.0–2.0) | 10.2 (8.4–11.9) |
| EF-Chul | ERY-GEN-KAN-LIN-NAL-NEO-OXA-POB-STR-SFX-TET-TMP-VAN | 6.4 (6.4–6.4) | 8.4 (8.4–16.7) | >120 | 10.2 (7.9–15.9) |
| D2.20, L2.4, and M2.01 | NAL-NEO-OXA-POB-STR-SFX-TET | 12.8 (12.8–25.6) | 9.4 (8.4–20.9) | 4.0 (2.0–4.0) | 8.4 (4.2–15.9) |
| HL 1148 | LIN-NAL-OXA-POB-STR-SFX-TET | 6.4 (6.4–12.8) | 16.7 (16.7–33.4) | 4.0 (3.8–7.5) | 31.7 (22.4–44.8) |
| HL 900 | GEN-KAN-LIN-NAL-NEO-OXA-POB-RIF-STR-SFX-TET | 12.8 (8.0–25.6) | 9.4 (8.4–20.9) | 4.0 (4.0–4.0) | 11.9 (8.4–15.9) |
| Enterococcus hirae ATCC 8043 | CEF-LIN-NAL-NEO-OXA-POB-STR-SFX | 12.8 (6.4–16.0) | 16.7 (16.7–20.9) | 4.0 (4.0–4.0) | 8.4 (8.4–7.9) |
| Staphylococcus aureus | |||||
| ATCC 43300 | AMP-PEN | 3.2 (3.2–6.4) | 10.1 (8.4–17) | 2.8 (1.9–8.0) | 7.9 (4.0–15.9) |
| M3.18 | AMP-PEN | 3.2 (1.6–3.2) | 8.4 (4.2–8.4) | 3.8 (3.8–5.3) | 1.0 (0.5–2.0) |
| R621 | AMP-ERY-OXA-PEN | 3.2 (3.2–3.2) | 8.4 (5.9–8.4) | 2.3 (1.9–3.8) | 23.8 (15.9–31.7) |
| R629, R630, and R694 | AMP-OXA-PEN | 1.6 (1.1–3.2) | 2.5 (2.1–8.4) | 2.3 (1.9–3.8) | 31.7 (22.4–63.4) |
| R650 | AMP-KAN-NAL-OXA-PEN-STR-TET | 3.2 (3.2–4.5) | 8.4 (4.2–8.4) | 3.8 (3.8–3.8) | 44.8 (15.9–63.4) |
| R678 | AMP-ERY-KAN-LIN-NAL-OXA-PEN | 3.2 (3.2–3.2) | 8.4 (4.2–8.4) | 2.7 (1.9–3.8) | 15.9 (15.9–63.4) |
| R695 | AMP-OXA-PEN-TMP | 3.2 (3.2–3.2) | 5.9 (5.9–8.4) | 2.7 (1.9–2.7) | 31.7 (15.9–63.4) |
| Staphylococcus epidermidis | |||||
| ATCC 12228 | AMP-PEN-SFX-TET | 0.8 (0.8–1.6) | 2.1 (2.1–6.0) | 2.0 (2.0–4.0) | 0.3 (0.1–0.4) |
| HL 3176 | AMP-ERY-KAN-LIN-OXA-PEN | 1.6 (0.8–1.6) | 3.0 (2.1–4.2) | 3.8 (2.0–4.0) | >127 |
| HL 1656 | AMP-ERY-KAN-LIN-OXA-PEN-RIF-STR-TET | 1.6 (1.1–3.2) | 3.0 (2.1–4.2) | 4.0 (2.0–4.0) | 8.4 (7.9–15.9) |
| Staphylococcus haemolyticus HL 2344 | AMP-CHL-ERY-KAN-LIN-NAL-OXA-PEN-STR-TET-TMP | 0.8 (0.8–0.8) | 4.2 (2.1–4.2) | 2.8 (1.9–4.0) | >127 |
| Staphylococcus xylosus BALB/c | NAL | 0.2 (0.2–0.4) | 8.4 (8.4–16.7) | 0.3 (0.3–0.5) | 0.5 (0.5–0.8) |
| Staphylococcus saprophyticus BALB/c | NAL | 0.2 (0.1–0.4) | 2.1 (2.1–2.1) | 2.0 (2.0–4.0) | 2.1 (2.1–2.1) |
a
Established by the antimicrobial disk susceptibility test. AMP, ampicillin; CEF, cephalothin; CHL, chloramphenicol; ERY, erythromycin; GEN, gentamicin; KAN, kanamycin; LIN, lincomycin; NAL, nalidixic acid; NEO, neomycin; OXA, oxacillin; PEN, penicillin; POB, polymyxin B; RIF, rifampin; STR, streptomycin; SFX, sulfisoxazole; TET, tetracycline; TMP, trimethoprim; VAN, vancomycin.
b
The MIC data are expressed as the median (range) obtained from at least three independent repetitions.